Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial

• Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disease.

• Relative to the vehicle, a statistically significant reduction in ocular redness was observed following treatment with reproxalap as soon as 10 minutes after dry eye chamber entry.

• The Schirmer test, assessed approximately 10 minutes before and after the fourth dose of reproxalap or vehicle, was statistically significant in favor of reproxalap at both time points.

• Also Read: Why Aldeyra Therapeutics' Shares Are Soaring Today?

• No safety signals were observed in the trial, and reproxalap was well tolerated; there were no treatment-emergent moderate or serious adverse events.

• Three patients were discontinued due to adverse events, two during vehicle administration and one during reproxalap administration. Reproxalap has now been studied in over 1,800 patients.

• A pre-NDA meeting with the FDA has been scheduled for Q3 of 2022.

• Price Action: ALDX shares are up 6.26% at $4.75 during the premarket session on the last check Tuesday.

See more from Benzinga

• BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program

• AngioDynamics' Q4 Top-Line Beats Street View, Issues Mixed FY23 Guidance

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.